MACCS CVTeam Education
The Late Breakers: What you must know from ACC.25

Get up to speed on the top late breaking clinical trials that were presented in Chicago at ACC.25.  Grab your cup of coffee, log on and quickly understand what your patients are going to be asking about and how it applies to your practice. This free session will enlighten and be enjoyable.   

Date: April 26, 2025

Time: 8:00am-10:00am

Location: Zoom

Register Today! 

MDACC

Updates in Coronary Artery Disease Trials from ACC.25

 

Moderator

John Lindsley, PharmD

Johns Hopkins Medicine

 

Speaker

Amy Dukovcic MSN, CRNP, MBA

LifeBridge Health Sinai Hospital

 

PaACC

Moderator
Maureen Julien, CRNP, AACC

Penn Medicine

Speaker

Brian McCauley, MD

Tower Health

 

• Routine Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation: The British Heart Foundation (BHF) PROTECT-TAVI Trial
• Clinical And Echocardiographic Outcomes Among the First 500 Patients Treated With a Dedicated Transcatheter Aortic Valve For Pure Aortic Regurgitation in the Align-AR Clinical Trial
• 5-year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
• Two-Year Outcomes of Transcatheter Tricuspid Valve Edge-to-Edge Repair For Tricuspid Regurgitation: The Triluminate Pivotal Trial

VCACC

Moderator

Steve Dunn, PharmD

University of Virginia Health System

 

Speaker

TBA

 

• Efficacy of Lorundrostat, A Novel Aldosterone Synthase Inhibitor, In Patients With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen 
• Oral Semaglutide Reduces Cardiovascular Events in People With Type 2 Diabetes With Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

• Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation